Northwire Canada EditionFriday, October 16, 2026
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%
Production / Operations

Cannara Achieves #1 Market Share Position in Quebec as of December 2025 and Provides Update on Quebec Vape Category Launch

LOVE · Price

Executive Summary

  • Cannara Biotech reports a strong preliminary performance in Quebec’s newly launched vape cartridge category, achieving a 29.7% share of retail sales value and securing the #1 market‑share position by total cannabis retail sales in December 2025 (14.7% share).
  • The board cancelled and re‑issued 544,600 stock options (including 515,000 held by insiders) to correct an administrative oversight; no net increase in outstanding options resulted.
  • Accelerated vesting of 15,000 RSUs for the late former director Jack Kay was approved, effective Dec 31 2025.

Key Details

  • Vape Category Launch Performance
  • Estimated retail sales data (Nov‑Dec 2025) show Cannara holding a 29.7% share of category sales value.
  • December 2025 market‑share: #1 in Quebec by total cannabis retail sales, 14.7% share (up 100 basis points month‑over‑month).

  • Executive Comments

  • Zohar Krivorot, President & CEO – highlighted the launch of 5 SKUs and strong consumer demand for premium vapes.
  • Nicholas Sosiak, CFO – emphasized the vertically integrated platform enabling premium rosin vape cartridges and live resin vapes.

  • Stock Option Cancellation & Re‑Issuance

  • Board approval date: Dec 31 2025; re‑issuance to occur on Jan 2 2026.
  • Total options affected: 544,600 (including 515,000 held by directors/officers).
  • Exercise prices & expiries: 500,000 options at $1.44 expiring Aug 27 2035; 15,000 options at $1.80 expiring Nov 20 2032.
  • No net increase in outstanding options; terms (exercise price, vesting schedule, expiry) remain unchanged.

  • Shareholder Proposal

  • At the Annual General & Special Meeting (Jan 29 2026), shareholders will be asked to approve conversion of the rolling Stock Option Plan and RSU Plan to fixed‑percentage plans (15% of outstanding shares).
  • TSX Venture Exchange has given conditional approval, pending shareholder vote.

  • Accelerated Vesting of RSUs

  • Board approved accelerated vesting of 15,000 restricted share units previously granted to the late Jack Kay, effective Dec 31 2025, to comply with plan terms after his passing on Nov 8 2025.

Notable Quotes

  • “The vape cartridge category launch in our home province of Québec has been a valuable opportunity to further expand our position as Canada’s #1 premium vape producer.” – Zohar Krivorot, President & CEO
  • “We are pleased to see strong reception to the launch of our first‑ever rosin vape cartridge offerings… we look forward to the continued consumer adoption of the category.” – Nicholas Sosiak, CFO
Read the original news release →

More from Cannara Biotech Inc.